Pharmacokinetics of vancomycin when administered during high flux hemodialysis
- PMID: 9710347
Pharmacokinetics of vancomycin when administered during high flux hemodialysis
Abstract
This study was undertaken to evaluate the pharmacokinetics of relatively high-dose vancomycin when administered during high-flux hemodialysis using a polysulfone membrane (F-80, Fresenius). Five noninfected, anuric patients received a single dose of 25 mg/kg of vancomycin infused during hemodialysis at a rate of one gram per hour and timed such that the end of the infusion coincided with the end of dialysis. Blood samples were drawn during the infusion, up to six hours after the end of dialysis and then prior to the next three dialysis treatments. Spent dialysate was collected during the infusion. Samples were analyzed using the EMIT assay. The percent of vancomycin lost during the first dialysis session ranged from 39.1 to 55.1% (mean, 45.7+/-6.4). The concentration of vancomycin at 6 hours after hemodialysis ranged from 18.2 to 45.1 mg/L (mean, 29.6+/-10.0 mg/l). Dialysis clearance ranged from 96.1 to 158.1 ml/min (mean, 130.7 +/-30.0 ml/min). One week after dosing, serum concentrations ranged from 8.14 mg/l to 10.1 mg/l (mean, 9.0+/-1.0 mg/l). This study suggests than an initial dose of 25 mg/kg of vancomycin, given during high-flux dialysis, may provide adequate serum concentrations in anuric hemodialysis patients for up to seven days. This dosing scheme reduces inconvenience to the patient and staff, and potentially can reduce nursing costs associated with post-dialysis administration; its cost is minimal. At this point, subsequent dosing is best determined by therapeutic drug monitoring.
Similar articles
-
Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.Clin Pharmacol Ther. 1998 Jan;63(1):26-38. doi: 10.1016/S0009-9236(98)90118-7. Clin Pharmacol Ther. 1998. PMID: 9465839
-
Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.Am J Kidney Dis. 2005 Oct;46(4):681-7. doi: 10.1053/j.ajkd.2005.07.018. Am J Kidney Dis. 2005. PMID: 16183423
-
Clearance of vancomycin during high-efficiency hemodialysis.J Med Assoc Thai. 2006 Jul;89(7):986-91. J Med Assoc Thai. 2006. PMID: 16881431
-
Vancomycin dosing in patients on intermittent hemodialysis.Semin Dial. 2011 Jan-Feb;24(1):50-5. doi: 10.1111/j.1525-139X.2010.00803.x. Semin Dial. 2011. PMID: 21338394 Review.
-
Drug dosing considerations in alternative hemodialysis.Adv Chronic Kidney Dis. 2007 Jul;14(3):e17-26. doi: 10.1053/j.ackd.2007.03.004. Adv Chronic Kidney Dis. 2007. PMID: 17603971 Review.
Cited by
-
Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis.Can J Hosp Pharm. 2016 Sep-Oct;69(5):341-347. doi: 10.4212/cjhp.v69i5.1588. Epub 2016 Oct 31. Can J Hosp Pharm. 2016. PMID: 27826151 Free PMC article.
-
Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation.BMC Nephrol. 2023 Sep 14;24(1):270. doi: 10.1186/s12882-023-03314-y. BMC Nephrol. 2023. PMID: 37710245 Free PMC article.
-
Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.Br J Clin Pharmacol. 2004 Sep;58(3):259-68. doi: 10.1111/j.1365-2125.2004.02143.x. Br J Clin Pharmacol. 2004. PMID: 15327585 Free PMC article.
-
Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review.BMC Nephrol. 2018 Mar 27;19(1):72. doi: 10.1186/s12882-018-0845-1. BMC Nephrol. 2018. PMID: 29587650 Free PMC article. Review.
-
Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis.Clin J Am Soc Nephrol. 2009 Jul;4(7):1190-4. doi: 10.2215/CJN.01650309. Epub 2009 Jun 18. Clin J Am Soc Nephrol. 2009. PMID: 19541812 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical